News
06-07-2011, 02:11 AM
ZIOPHARM Oncology, Inc. announced today that Douglas J. Schwartzentruber, MD, FACS, of the Indiana University Health Goshen Center for Cancer Care, presented initial positive clinical results from the first-ever treatment demonstrating control over transgene encoding of a therapeutic anticancer protein in humans using a small molecule activator ligand.
More... (http://www.news-medical.net/news/20110607/Initial-positive-results-from-ZIOPHARMs-ZIN-CTI-001-Phase-Ib-study-against-advanced-melanoma.aspx)
More... (http://www.news-medical.net/news/20110607/Initial-positive-results-from-ZIOPHARMs-ZIN-CTI-001-Phase-Ib-study-against-advanced-melanoma.aspx)